Core Viewpoint - Armata Pharmaceuticals, Inc. (ARMP) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements. Institutional investors utilize these estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. - The upgrade for Armata Pharmaceuticals suggests an improvement in its underlying business, which is expected to drive the stock price higher as investors respond to this trend [3]. Earnings Estimate Revisions - For the fiscal year ending December 2024, Armata Pharmaceuticals is projected to earn -$1.02 per share, reflecting a 46.6% change from the previous year's reported figure [5]. - Over the past three months, the Zacks Consensus Estimate for Armata Pharmaceuticals has increased by 46.5%, indicating a positive trend in earnings estimates [5]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [4]. - The upgrade of Armata Pharmaceuticals to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [7].

Core Insights - Armata Pharmaceuticals is focused on developing high-purity, pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant bacterial infections [1][6] - The company is presenting its phage development programs at the 2024 Military Health System Research Symposium, highlighting two candidates: inhaled AP-PA02 for Pseudomonas aeruginosa bronchiectasis and intravenous AP-SA02 for Staphylococcus aureus bacteremia [1][4] Clinical Development - The Phase 1b/2a diSArm study for intravenous AP-SA02 is 80% enrolled, with completion expected by the end of 2024 [2] - The clinical development of AP-SA02 is supported by a $21.6 million grant from the Department of Defense [2] - Preliminary data indicates that both intravenous AP-SA02 and inhaled AP-PA02 have been well tolerated, with promising pharmacokinetic results suggesting potential clinical benefits [4] Future Plans - The company aims to advance both AP-SA02 and AP-PA02 into pivotal Phase 3 trials in 2025, with the goal of introducing a new class of anti-infectives [3][4] - The poster presentation at MHSRS will discuss the ongoing clinical trials and their implications for treating difficult-to-treat infections [4][5] Company Overview - Armata Pharmaceuticals is a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant infections, utilizing proprietary technology [6] - The company is developing a pipeline of natural and synthetic phage candidates targeting various pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus [6]

LOS ANGELES, Aug. 15, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced the appointment of life sciences accounting and finance veteran David House as Senior Vice President, Finance, effective August 16th. Armata's Corporate Controller, Richard Rychlik, will reta ...

LOS ANGELES, Aug. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2024, and provided a corporate update. Second Quarter 2024 and Recent Developments: Announced completion of enrollment in its Tailwind Phase 2 clinical st ...

Phase 1b/2a diSArm trial evaluating AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia  LOS ANGELES, July 30, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $5.25 million of non-dilutive funding ...

LOS ANGELES, July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will deliver a presentation at Viruses of Microbes 2024, which is being held July 15-19, 2024, in Cairns, Australia.   Details of the presentation are as follo ...

Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES, March 4, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportun ...

LOS ANGELES, Feb. 21, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Mina Pastagia, M.D., Chief Medical Officer, will deliver a presentation at the 6th Annual Bacteriophage Therapy Summit, which is being held February 27-29 in Boston. Details of the presentation are as follows: Title:   ...